Summary

The global market for Neuromyelitis Optica Drug was estimated to be worth US$ 49.8 million in 2024 and is forecast to a readjusted size of US$ 61.1 million by 2031 with a CAGR of 3.0% during the forecast period 2025-2031.
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord. Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
The Neuromyelitis Optica (NMO) drug market is being significantly driven by the rising prevalence and improved diagnosis of this rare autoimmune disorder, also known as Neuromyelitis Optica Spectrum Disorder (NMOSD). Increased awareness among healthcare professionals, coupled with advancements in diagnostic technologies such as AQP4-IgG antibody testing, has led to earlier and more accurate diagnosis of NMO, thereby increasing the number of patients eligible for treatment. Furthermore, the approval of targeted therapies like eculizumab, inebilizumab, and satralizumab in recent years has transformed the treatment landscape, offering more effective and specific interventions compared to traditional immunosuppressants. These breakthroughs have not only improved patient outcomes but have also stimulated investment and innovation in NMO drug development. The growing focus on orphan diseases by pharmaceutical companies, supported by favorable regulatory incentives such as orphan drug designations and fast-track approvals, is further fueling market growth. In addition, increasing healthcare expenditure, especially in developed regions, and a stronger patient advocacy movement are contributing to greater access to treatment and awareness about this once-overlooked condition.
Despite promising developments, the NMO drug market faces several challenges that may hinder its long-term growth. First, the high cost of newly approved biologic therapies poses a significant barrier to access, particularly in low- and middle-income countries where reimbursement systems are weak or nonexistent. The pricing of drugs like eculizumab, which can cost hundreds of thousands of dollars per year, places a heavy burden on both healthcare systems and patients, potentially limiting widespread adoption. Additionally, NMO is a rare and complex disease, which makes it difficult to recruit sufficient participants for large-scale clinical trials, slowing the pace of drug development and innovation. The heterogeneity of disease presentation and overlapping symptoms with multiple sclerosis also pose diagnostic challenges, which can lead to misdiagnosis and inappropriate treatment. Moreover, long-term safety data for newer therapies are still limited, which may create hesitation among clinicians and regulatory bodies when adopting these treatments on a broader scale. Lastly, the market remains highly specialized, with few pharmaceutical players involved, leading to limited competition and potential supply chain vulnerabilities. Addressing these issues will be essential to ensuring that recent advancements in NMO treatment translate into improved outcomes for patients across different healthcare environments.
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Neuromyelitis Optica Drug by region & country, by Type, and by Application.
The Neuromyelitis Optica Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Drug.
Market Segmentation
By Company
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Segment by Type
Glucocorticoids
Immunotherapies
Others
Segment by Application
Acute Attack
Remission Prophylactic Treatment
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Neuromyelitis Optica Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Neuromyelitis Optica Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Neuromyelitis Optica Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Neuromyelitis Optica Drug Product Introduction
1.2 Global Neuromyelitis Optica Drug Market Size Forecast (2020-2031)
1.3 Neuromyelitis Optica Drug Market Trends & Drivers
1.3.1 Neuromyelitis Optica Drug Industry Trends
1.3.2 Neuromyelitis Optica Drug Market Drivers & Opportunity
1.3.3 Neuromyelitis Optica Drug Market Challenges
1.3.4 Neuromyelitis Optica Drug Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Neuromyelitis Optica Drug Players Revenue Ranking (2024)
2.2 Global Neuromyelitis Optica Drug Revenue by Company (2020-2025)
2.3 Key Companies Neuromyelitis Optica Drug Manufacturing Base Distribution and Headquarters
2.4 Key Companies Neuromyelitis Optica Drug Product Offered
2.5 Key Companies Time to Begin Mass Production of Neuromyelitis Optica Drug
2.6 Neuromyelitis Optica Drug Market Competitive Analysis
2.6.1 Neuromyelitis Optica Drug Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Neuromyelitis Optica Drug Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Glucocorticoids
3.1.2 Immunotherapies
3.1.3 Others
3.2 Global Neuromyelitis Optica Drug Sales Value by Type
3.2.1 Global Neuromyelitis Optica Drug Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Neuromyelitis Optica Drug Sales Value, by Type (2020-2031)
3.2.3 Global Neuromyelitis Optica Drug Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Acute Attack
4.1.2 Remission Prophylactic Treatment
4.2 Global Neuromyelitis Optica Drug Sales Value by Application
4.2.1 Global Neuromyelitis Optica Drug Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Neuromyelitis Optica Drug Sales Value, by Application (2020-2031)
4.2.3 Global Neuromyelitis Optica Drug Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Neuromyelitis Optica Drug Sales Value by Region
5.1.1 Global Neuromyelitis Optica Drug Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Neuromyelitis Optica Drug Sales Value by Region (2020-2025)
5.1.3 Global Neuromyelitis Optica Drug Sales Value by Region (2026-2031)
5.1.4 Global Neuromyelitis Optica Drug Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Neuromyelitis Optica Drug Sales Value, 2020-2031
5.2.2 North America Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Neuromyelitis Optica Drug Sales Value, 2020-2031
5.3.2 Europe Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Neuromyelitis Optica Drug Sales Value, 2020-2031
5.4.2 Asia Pacific Neuromyelitis Optica Drug Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Neuromyelitis Optica Drug Sales Value, 2020-2031
5.5.2 South America Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Neuromyelitis Optica Drug Sales Value, 2020-2031
5.6.2 Middle East & Africa Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Neuromyelitis Optica Drug Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Neuromyelitis Optica Drug Sales Value, 2020-2031
6.3 United States
6.3.1 United States Neuromyelitis Optica Drug Sales Value, 2020-2031
6.3.2 United States Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Neuromyelitis Optica Drug Sales Value, 2020-2031
6.4.2 Europe Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Neuromyelitis Optica Drug Sales Value, 2020-2031
6.5.2 China Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
6.5.3 China Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Neuromyelitis Optica Drug Sales Value, 2020-2031
6.6.2 Japan Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Neuromyelitis Optica Drug Sales Value, 2020-2031
6.7.2 South Korea Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Neuromyelitis Optica Drug Sales Value, 2020-2031
6.8.2 Southeast Asia Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Neuromyelitis Optica Drug Sales Value, 2020-2031
6.9.2 India Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
6.9.3 India Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Profile
7.1.2 Pfizer Main Business
7.1.3 Pfizer Neuromyelitis Optica Drug Products, Services and Solutions
7.1.4 Pfizer Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
7.1.5 Pfizer Recent Developments
7.2 Fresenius
7.2.1 Fresenius Profile
7.2.2 Fresenius Main Business
7.2.3 Fresenius Neuromyelitis Optica Drug Products, Services and Solutions
7.2.4 Fresenius Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
7.2.5 Fresenius Recent Developments
7.3 Teva
7.3.1 Teva Profile
7.3.2 Teva Main Business
7.3.3 Teva Neuromyelitis Optica Drug Products, Services and Solutions
7.3.4 Teva Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
7.3.5 Teva Recent Developments
7.4 Sandoz
7.4.1 Sandoz Profile
7.4.2 Sandoz Main Business
7.4.3 Sandoz Neuromyelitis Optica Drug Products, Services and Solutions
7.4.4 Sandoz Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
7.4.5 Sandoz Recent Developments
7.5 Intas
7.5.1 Intas Profile
7.5.2 Intas Main Business
7.5.3 Intas Neuromyelitis Optica Drug Products, Services and Solutions
7.5.4 Intas Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
7.5.5 Intas Recent Developments
7.6 Gyjtrs
7.6.1 Gyjtrs Profile
7.6.2 Gyjtrs Main Business
7.6.3 Gyjtrs Neuromyelitis Optica Drug Products, Services and Solutions
7.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
7.6.5 Gyjtrs Recent Developments
7.7 NANG KUANG
7.7.1 NANG KUANG Profile
7.7.2 NANG KUANG Main Business
7.7.3 NANG KUANG Neuromyelitis Optica Drug Products, Services and Solutions
7.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
7.7.5 NANG KUANG Recent Developments
7.8 Tianjin Kingyork
7.8.1 Tianjin Kingyork Profile
7.8.2 Tianjin Kingyork Main Business
7.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Products, Services and Solutions
7.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
7.8.5 Tianjin Kingyork Recent Developments
7.9 Baxter
7.9.1 Baxter Profile
7.9.2 Baxter Main Business
7.9.3 Baxter Neuromyelitis Optica Drug Products, Services and Solutions
7.9.4 Baxter Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
7.9.5 Baxter Recent Developments
7.10 CSL
7.10.1 CSL Profile
7.10.2 CSL Main Business
7.10.3 CSL Neuromyelitis Optica Drug Products, Services and Solutions
7.10.4 CSL Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
7.10.5 CSL Recent Developments
7.11 Grifols
7.11.1 Grifols Profile
7.11.2 Grifols Main Business
7.11.3 Grifols Neuromyelitis Optica Drug Products, Services and Solutions
7.11.4 Grifols Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
7.11.5 Grifols Recent Developments
7.12 Octapharma
7.12.1 Octapharma Profile
7.12.2 Octapharma Main Business
7.12.3 Octapharma Neuromyelitis Optica Drug Products, Services and Solutions
7.12.4 Octapharma Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
7.12.5 Octapharma Recent Developments
7.13 CBOP
7.13.1 CBOP Profile
7.13.2 CBOP Main Business
7.13.3 CBOP Neuromyelitis Optica Drug Products, Services and Solutions
7.13.4 CBOP Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
7.13.5 CBOP Recent Developments
8 Industry Chain Analysis
8.1 Neuromyelitis Optica Drug Industrial Chain
8.2 Neuromyelitis Optica Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Neuromyelitis Optica Drug Sales Model
8.5.2 Sales Channel
8.5.3 Neuromyelitis Optica Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer